Stocksigma LogoStocksigma Logo

CARE Edge Reports Zero Deviation in Symbiotec Pharmalab's IPO Proceeds Utilization

CARE Edge Ratings issued its Monitoring Agency report for Symbiotec Pharmalab for the quarter ended 30th Sep'26, confirming zero deviation from stated IPO

CARE Edge Reports Zero Deviation in Symbiotec Pharmalab's IPO Proceeds Utilization

Symbiotec Pharmalab Ltd · Others (Uncategorized) · 06 Nov 2026, 2:04 am

CARE Edge Reports Zero Deviation in Symbiotec Pharmalab's IPO Proceeds Utilization CARE Edge Ratings issued its Monitoring Agency report for Symbiotec Pharmalab for the quarter ended 30th Sep'26, confirming zero deviation from stated IPO objectives. Out of ₹150.00 crore raised via fresh issue proceeds, the company deployed ₹143.59 crore during the quarter. Key capital allocations include ₹112.50 crore fully utilized for debt prepayment/repayment, ₹29.50 crore deployed for general corporate working capital requirements (out of ₹29.53 crore allocated), and ₹1.59 crore toward offer-related expenses. Unutilized funds totaling ₹6.41 crore remain parked in designated bank accounts.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements